To include your compound in the COVID-19 Resource Center, submit it here.

Disappointing delay for Gensia

Disappointing delay for Gensia

Gensia Inc. on Friday said that it had run into a snag in the initial scale-up of its formulation of Geomatrix nifedipine, and that further formulation will be required.

As

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE